利拉鲁肽及胰岛素泵治疗 2 型糖尿病合并急性肾功能衰竭 1 例
摘要
患者 52 岁男性，因“间断胸闷气短 1 年，加重 1 周”入院，查血肌酐 768.60umol/L，糖化血红蛋白 10.1%，给予胰岛素泵
联合利拉鲁肽注射液治疗，血糖控制满意，复查肾功能正常。
关键词
全文:
PDF参考
[1] 中华医学会糖尿病学分会 . 中国 2 型糖尿病防治指
南 (2020 年版 )[J]. 中华糖尿病杂志 , 2021, 13(04):315409.
[2]Zhang L, Long J, Jiang W, et al. Trends in chronic kidney
disease in China[J]. N Engl J Med,
2016,375(9):905906.DOI: 10.1056/NEJMc1602469.
[3] American Diabetes Association. 11. Microvascular
complications and foot care: standards of medical care in
diabetes2020[J]. Diabetes Care, 2020, 43 Suppl 1: S135S151.
DOI: 10.2337/dc20S011.
[4] Luk A, Hui E, Sin MC, et al. Declining trends of
cardiovascularrenal complications and mortality in type 2
diabetes: the Hong Kong diabetes database[J]. Diabetes Care,
2017,40(7):928935.
[5] 北京大学医学系糖尿病肾脏病专家共识协作组 . 糖
尿病肾脏病诊治专家共识 [J]. 中华医学杂志 , 2020, 100(4):
247260.
[6] Bisgaard LS, Bosteen MH, Fink LN, et al. Liraglutide
reduces both atherosclerosis and kidney inflammation in
moderately uremic LDLr/Mice[J]. PLoS One,2016,11(12).
[7]Skov J, Dejgaard A, Frøkiær J, et al. Glucagonlike
peptide1 (GLP1): effect on kidney hemody namics and
reninangiotensinaldosterone system in healthy men[J]. J Clin
Endocrinol Metab,2013,98(4):664671.
[8]Mann J, Ørsted DD, BrownFrandsen K, et al. Liraglutide
and renal outcomes in type 2 diabetes[J]. N Engl J Med, 2017,
377(9):839848.
[9]Muskiet M, Tonneijck L, Smits MM, et al. GLP1 and
the kidney: from physiology to pharmacology and outcomes in
diabetes[J]. Nat Rev Nephrol,2017,13(10): 605628.
[10] Marso SP, Daniels GH, BrownFrandsen K, et al.
Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N
Engl J Med, 2016, 375(4): 311322.
[11] Roth GA, Mensah GA, Johnson CO, et al. Global burden
of cardiovascular diseases and risk factors, 19902019: update from
the GBD 2019 Study[J]. J Am Coll Cardiol, 2020,76(25):29823021.
[12] Draznin B,Aroda VR,et al. 9. Pharmacologic approaches
to glycemic treatment: standards of medical care in diabetes-
2022[J]. Diabetes Care,2022,45(1):S125-S143.
[13] Sattar N , Lee MMY, Kristensen SL, et al.
Cardiovascular, mortality, and kidney outcomes with GLP-1
receptor agonists in patients with type 2 diabetes: a systematic
review and meta-analysis of randomised trials.Lancet Diabetes
Endocrinol,2021(9):653–662.
[14] Berndt J,Ooi SL,Pak SC.What Is the Mechanism
Driving the Reduction of Cardiovascular Events from Glucagonlike Peptide-1 Receptor Agonists? -A Mini Review [J].
Molecules,2021,26(16):4822.
[15] Zinman B, Schmidt WE, Moses A, et al. Achieving
a clinically relevantcomposite outcome of an HbA1c of <7%
withoutweightgain orhypoglycaemiain type2 diabetes:a metaanalysisofthe liraglutideclinicaltrial programme[J] . Diabetes Obes
Metab, 2012, 14(1) : 77-82.
[16]Loganathan J,Cohen AC, Kaloupis GM , et al. A pilot
clinical study to Evaluate Liraglutide-mediated Anti- platelet
activity in patients with type-2 Diabetes (ELAID study) [J] . J
Diabetes Complications,2022,36(5) :108188.
[17] 赵延珍 , 杜婧 . GLP1 受体激动剂治疗 2 型糖尿病的
研究进展 [J]. 老年医学研究 ,2021,2(3):5560.
[18] Dandona P, Ghanim H , ChaudhuriA. Incretins:
Be- yond type2diabetes[J] . Diabetes Obes Metab, 2018,
20Suppl1:59-67.
[19] SecherA,JelsingJ,BaqueroAF,etal. Thearcuatenucleus mediates GLP-1receptor agonist liraglutide-dependentweightloss[J] . J Clin Invest,2014,124(10):4473-4488.
(7 摘要 Views, 5 PDF Downloads)
Refbacks
- 当前没有refback。